Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00516295
Other study ID # NCI-2009-00369
Secondary ID NCI-2009-00369AE
Status Completed
Phase Phase 2
First received August 14, 2007
Last updated August 20, 2014
Start date February 2008
Est. completion date January 2010

Study information

Verified date July 2014
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase II trial study has a 6-patient feasibility portion studying the tolerability of chemotherapy with vincristine sulfate together with topotecan hydrochloride, cyclophosphamide, and bevacizumab in treating young patients with refractory or first recurrent extracranial Ewing's sarcoma. If the therapy is considered tolerable, this feasibility run-in will be followed by a randomized phase II portion studying giving vincristine sulfate together with topotecan hydrochloride, and cyclophosphamide to see how well it works compared with giving vincristine sulfate together with topotecan hydrochloride, cyclophosphamide, and bevacizumab in treating young patients with refractory or first recurrent extracranial Ewing's sarcoma. Drugs used in chemotherapy, such as vincristine sulfate, topotecan hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop tumor growth by blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab may kill more tumor cells.


Description:

PRIMARY OBJECTIVES:

I. To determine the feasibility of administering bevacizumab in combination with vincristine (vincristine sulfate), topotecan hydrochloride, and cyclophosphamide (VTC) to younger patients with refractory or first recurrent Ewing sarcoma.

II. To compare the progression-free survival of patients treated with VTC with bevacizumab vs VTC without bevacizumab.

SECONDARY OBJECTIVES:

I. To estimate the response rate to 2 cycles of VTC compared to 2 cycles of VTC/bevacizumab.

II. To evaluate biological markers as related to prognosis and specifically related to angiogenesis by encouraging concurrent enrollment on the Ewing sarcoma banking studies (COG-AEWS02B1 and/or COG-AEWS07B1) and ancillary correlative endothelial cell, surrogate marker, and angiogenic gene studies.

OUTLINE: This is a single therapy feasibility study followed by a randomized controlled portion. Patients are stratified according to time to disease recurrence (< 2 years vs >= 2 years).

ARM I (Feasibility assessment of VTCB): Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, vincristine sulfate IV on days 1, 8, and 15, and topotecan hydrochloride IV over 30 minutes and cyclophosphamide IV over 60 minutes on days 1-5. Treatment repeats every 21 days (except during weeks 14, 15 [course 5], 17, 18 [course 6], 26, 27 [course 9], 29, and 30 [course 10] when no chemotherapy is given) for up to 12 courses in the absence of disease progression or unacceptable toxicity.

ARM II (VTCB): Patients receive bevacizumab, vincristine sulfate, topotecan hydrochloride, and cyclophosphamide as in Arm I.

ARM III (VTC): Patients receive vincristine sulfate, topotecan hydrochloride, and cyclophosphamide as in arm I.

After completion of study therapy, patients are followed periodically.


Recruitment information / eligibility

Status Completed
Enrollment 7
Est. completion date January 2010
Est. primary completion date August 2009
Accepts healthy volunteers No
Gender Both
Age group 1 Year to 29 Years
Eligibility Inclusion Criteria:

- ALT =< 5 times ULN for age

- Urine protein: creatinine ratio =< 0.5 OR 24-hour urine protein < 1,000 mg

- At least 6 weeks since other prior substantial bone marrow radiation

- At least 28 days since prior major surgical procedures (e.g., resection of tumor, laparotomy, thoracotomy, or open biopsy)

- At least 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas)

- At least 2 weeks since prior local palliative radiotherapy (e.g., small port)

- Diagnosis of extracranial Ewing sarcoma or primitive neuroectodermal tumor of bone or soft tissue meeting 1 of the following criteria: I) a first recurrence of localized disease; II) a first recurrence of initially metastatic disease; III) disease refractory to initial conventional therapy

- Patients must have RECIST-measurable disease documented by clinical, radiographic, or histological criteria

- Patients who do not have measurable disease (e.g., bone scan-determined metastatic disease only) remain eligible for the study and will be evaluable for disease-free progression

- Karnofsky performance status (PS) 50-100% (> 16 years of age) OR Lansky PS 50-100% (=< 16 years of age )

- Life expectancy >= 8 weeks

- Absolute neutrophil count >= 1,000/µL

- NOTE: Patients with tumor metastatic to bone marrow are permitted to receive transfusions to maintain hemoglobin and platelet counts. These patients will not be evaluable for hematologic toxicity. Patients who are refractory to platelet infusions (i.e., unable to maintain platelet counts > 75,000/µL) and have marrow involvement and platelet counts < 75,000/µL are not eligible

- Fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy

- At least 1 week since prior therapy with a biologic agent or growth factor

- Patients must have histological verification of the malignancy at original diagnosis

- Histological confirmation of relapse is highly recommended but not mandatory

- Prior initial therapy with topotecan hydrochloride is allowed as long as > 2 years have elapsed since the initial diagnosis of Ewing sarcoma

- Prior therapy with cyclophosphamide or vincristine is allowed

- Minor surgical procedures (e.g., biopsies) for limited purposes of tissue retrieval allowed

- Minor procedures include indwelling IV catheter placement and needle biopsy for diagnostic purposes

- For minor surgeries, patients should not receive the first planned dose of bevacizumab until the wound is healed and 7 days have elapsed

- At least 6 months since prior craniospinal radiotherapy or radiotherapy to >= 50% of the pelvis

- At least 3 months since prior autologous stem cell transplantation (SCT)

- Platelet count >= 75,000/µL (transfusion independent)

- Hemoglobin >= 8.0 g/dL (may receive RBC transfusions)

- Direct bilirubin =< 1.5 times upper limit of normal (ULN) for age

- Creatinine clearance or radioisotope GFR >= 70 mL/min OR serum creatinine normal for age

- Hypertension must be well controlled on stable doses of medication for >= 2 weeks prior to enrollment

- Negative pregnancy test

- Female patients who are lactating must agree to stop breast-feeding

- II) The patient has no active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)

- Shortening fraction > 28% OR ejection fraction > 50%

- Recovered from any prior surgical procedure

- Sexually active patients of childbearing potential must agree to use effective contraception

- Patients on full-dose anticoagulants (e.g., warfarin) with PT INR > 1.5 are eligible if both of these criteria are met:

- I) The patient has an in-range INR (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin

Exclusion Criteria:

- Radiological or clinical evidence for parenchymal brain metastases or neuro axis involvement

- Documented, chronic nonhealing wound, ulcer, or significant traumatic injury (those with bone fractures, including pathological fractures, or requiring surgical intervention) within the past 28 days

- Other bone complications

- Deep venous thrombosis (including pulmonary embolism) within the past 3 months

- Recent (i.e., within 6 months) arterial thromboembolic events, including transient ischemic attack or cerebrovascular accident

- History of myocardial infarction, severe or unstable angina, or peripheral vascular disease Prior bevacizumab

- Radiotherapy or surgery for local control of recurrent disease concurrently with bevacizumab (bevacizumab must be held if radiotherapy or surgery is required)

- Radiotherapy to localized painful lesions is allowed, provided >= 1 measurable lesion is not irradiated

- Radiotherapy for local metastatic tumor control allowed after the first 2 courses of therapy

- Other cancer chemotherapy or immunomodulating agents

- Steroid use is allowed

- Prior allogeneic SCT

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
topotecan hydrochloride
Given IV
vincristine sulfate
Given IV
cyclophosphamide
Given IV
Biological:
bevacizumab
Given IV

Locations

Country Name City State
United States Children's Oncology Group Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Occurrence of Limiting Toxicity in an Eligible and Evaluable Patient. Limiting toxicity defined as Any Grade IV hematological toxicities lasting longer than 7 days, myelosuppression causing delays > 14 days in delivery of therapy, > Grade 3 thromboembolic events, > Grade 3 bleeding events, > Grade 2 hypertension, > Grade 2 proteinuria. First 2 courses (42 days) of therapy Yes
Primary Time to Disease Progression in Patients Receiving VTC With or Without Bevacizumab Time from enrollment to disease progression, death, second malignant neoplasm, or last patient follow-up whichever occurs first. Patients who experience disease progression, death or second malignant neoplasm will be considered to have experienced an event; otherwise the patient will be considered censored at last follow-up. Maximum of 5 years after enrollment No
See also
  Status Clinical Trial Phase
Completed NCT00093821 - Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors Phase 1
Active, not recruiting NCT03233204 - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT00091182 - Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Phase 2
Completed NCT00004078 - Irinotecan in Treating Children With Refractory Solid Tumors Phase 2
Completed NCT00004241 - 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma Phase 1
Completed NCT00030667 - Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood Phase 2
Completed NCT02116777 - Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Phase 1/Phase 2
Completed NCT02304458 - Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Phase 1/Phase 2
Completed NCT00101270 - Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT03210714 - Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Withdrawn NCT02011126 - Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors Phase 2
Completed NCT00536601 - High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors N/A
Completed NCT01154452 - Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Phase 1/Phase 2
Completed NCT00330421 - Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) Phase 2
Completed NCT01614795 - Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Phase 2
Withdrawn NCT01795430 - Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma N/A
Completed NCT00609141 - IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor Phase 1
Active, not recruiting NCT00112463 - Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Phase 2
Completed NCT00048984 - Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma N/A
Completed NCT00899990 - Collecting and Storing Biological Samples From Patients With Ewing Sarcoma